Actively Recruiting
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Led by Merck Sharp & Dohme LLC · Updated on 2026-05-01
60
Participants Needed
7
Research Sites
115 weeks
Total Duration
On this page
Sponsors
M
Merck Sharp & Dohme LLC
Lead Sponsor
D
Daiichi Sankyo
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goal of this trial is to learn how many participants who receive I-DXd have the cancer respond, which means the cancer gets smaller or goes away.
CONDITIONS
Official Title
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Has a confirmed diagnosis of unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)
- Has disease progression after 1 or 2 prior systemic therapy treatments for ESCC
- Has measurable disease
- If infected with HIV, has well-controlled HIV on antiretroviral therapy
- Has adequate organ function
You will not qualify if you...
- Has adenocarcinoma or adenosquamous carcinoma subtype
- Has uncontrollable pleural effusion, pericardial effusion, or ascites needing frequent drainage or medical intervention
- Has clinically significant corneal disease
- Had cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event within 6 months before screening
- If infected with HIV, has history of Kaposi's sarcoma or Multicentric Castleman's Disease
- Has uncontrolled or significant cardiovascular disease
- Has another progressing malignancy requiring active treatment within the past 3 years
- Has active central nervous system metastases or carcinomatous meningitis
- Has history or current pneumonitis/interstitial lung disease or suspected pneumonitis/interstitial lung disease
- Has active infection requiring systemic therapy other than allowed
- Has severe lung problems from illnesses such as pulmonary emboli, severe asthma, severe COPD, restrictive lung disease, pleural effusion, autoimmune or inflammatory disorders, prior pneumonectomy, or needs supplemental oxygen
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Aichi Cancer Center ( Site 2702)
Nagoya, Aichi-ken, Japan, 464-8681
Actively Recruiting
2
Kanagawa Cancer Center ( Site 2701)
Yokohama, Kanagawa, Japan, 241-8515
Actively Recruiting
3
National Cancer Center Hospital ( Site 2700)
Chūō, Tokyo, Japan, 104-0045
Actively Recruiting
4
Asan Medical Center ( Site 2901)
Seoul, South Korea, 05505
Actively Recruiting
5
Samsung Medical Center ( Site 2900)
Seoul, South Korea, 06351
Actively Recruiting
6
Hopitaux Universitaires de Geneve HUG ( Site 3701)
Geneva, Switzerland, 1211
Actively Recruiting
7
National Cheng Kung University Hospital ( Site 3001)
Tainan, Taiwan, 704
Actively Recruiting
Research Team
T
Toll Free Number
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here